New silicon-based drugs made with Fuzionaire’s proprietary alkali metal catalyst platform could offer improved efficacy and reduced toxicity
THE WOODLANDS, Texas--(BUSINESS WIRE)--Fuzionaire, Inc. today announced a collaborative research agreement with McGill University that will leverage the company’s proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates.
New silicon-containing scaffolds, where a carbon atom is replaced with a silicon atom, would enable a wide array of new silicon-based drug candidates that could have improved efficacy and safety as compared to their carbon-based counterparts.
Silicon is the second-most abundant element in the Earth’s crust. Belonging to the same group in the periodic table as carbon, silicon shares many of its properties, including biocompatibility and low toxicity. Because of slight structural differences, a carbon/silicon switch can modify the biological properties of a drug and potentially enhance its efficacy and safety. Existing drugs that are currently disfavored because of poor biochemical or pharmacokinetic properties could be converted into new silicon forms and used to treat a wide array of diseases.
To date, silicon has not been well-explored in drug development because it is difficult to synthesize silicon-containing structures. Consequently, there are only a small number of silicon-containing compounds under current investigation for pharmaceutical use.
As a platform for the incorporation of silicon into organic molecules, Fuzionaire’s alkali metal catalyst platform could help pave the way for a larger role for silicon in the discovery and design of future generations of pharmaceuticals.
As initially reported in Nature, Fuzionaire’s patented technology enables the incorporation of silicon into organic molecules to create many previously unexplored organosilicon compounds. The synthetic technology is safe and based on an inexpensive potassium catalyst. This is in contrast with many other methods used for incorporating silicon, which often require expensive precious metal catalysts and have other practical limitations.
“The potential upside of using silicon in therapeutics has been recognized for decades, but progress in developing silicon drugs has been impeded, in part, by a lack of general methods to create organosilicon scaffolds,” said Jean-Philip Lumb, PhD, Associate Professor of Chemistry at McGill. “With new chemistry, new possibilities are created.”
“Silicon-based medicines will be an important part of the future of healthcare, and our goal is for our platform, and the library of scaffolds and pipeline of drug candidates developed with it, to help accelerate this future,” said Nick Slavin, co-founder and CEO of Fuzionaire.
Fuzionaire’s collaboration with the Lumb Lab to make new silicon-containing scaffolds and drug candidates will begin with a focus on oncology.
The expertise of McGill and the Lumb Lab in silicon chemistry is longstanding. Since 2020, Fuzionaire affiliate Fuzionaire Diagnostics has been working with McGill in the development of a library of heteroaromatic silicon-fluoride acceptors, or HetSiFAs®, as a platform to make diagnostic and theranostic radiopharmaceuticals.
Fuzionaire is a central laboratory developing new technologies and ventures based on discoveries in fundamental chemistry made at Caltech. Leveraging Earth-abundant, alkali metal catalysts and reagents, the way in which we make and break bonds is versatile, efficient, and sustainable, creating new opportunities in medicine, energy, and materials.
For more, visit us at: www.fuzionaire.com
Founded in Montreal, Quebec, in 1821, McGill University is Canada’s top ranked medical doctoral university. McGill is consistently ranked as one of the top universities, both nationally and internationally. It is a world-renowned institution of higher learning with research activities spanning three campuses, 11 faculties, 13 professional schools, 300 programs of study and over 39,000 students, including more than 10,400 graduate students.
Media Contact: Rebecca Ewing 903 215 0296 Jones-Dilworth, Inc.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.